Li et al.37reported that enzalutamide induces HR deficiency by suppressing the expression of BRCA1, RAD54L, and RMI2 in prostate cancer, thereby, enhancing the therapeutic effect of olaparib. This evidence concerns the gene RAD54L and prostate cancer.